ATE293119T1 - Cardioprotektive phosphonate - Google Patents

Cardioprotektive phosphonate

Info

Publication number
ATE293119T1
ATE293119T1 AT01909391T AT01909391T ATE293119T1 AT E293119 T1 ATE293119 T1 AT E293119T1 AT 01909391 T AT01909391 T AT 01909391T AT 01909391 T AT01909391 T AT 01909391T AT E293119 T1 ATE293119 T1 AT E293119T1
Authority
AT
Austria
Prior art keywords
hydroxymethyl
hydroxy
methyl
cardioprotective
phosphonates
Prior art date
Application number
AT01909391T
Other languages
English (en)
Inventor
Wasimul Haque
Original Assignee
Medicure Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicure Int Inc filed Critical Medicure Int Inc
Application granted granted Critical
Publication of ATE293119T1 publication Critical patent/ATE293119T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Materials For Medical Uses (AREA)
  • Credit Cards Or The Like (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AT01909391T 2000-02-29 2001-02-28 Cardioprotektive phosphonate ATE293119T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18589900P 2000-02-29 2000-02-29
PCT/CA2001/000265 WO2001064692A1 (en) 2000-02-29 2001-02-28 Cardioprotective phosphonates and malonates

Publications (1)

Publication Number Publication Date
ATE293119T1 true ATE293119T1 (de) 2005-04-15

Family

ID=22682882

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01909391T ATE293119T1 (de) 2000-02-29 2001-02-28 Cardioprotektive phosphonate
AT05075063T ATE389662T1 (de) 2000-02-29 2001-02-28 Cardioprotektive phosphonate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05075063T ATE389662T1 (de) 2000-02-29 2001-02-28 Cardioprotektive phosphonate

Country Status (11)

Country Link
US (5) US6605612B2 (de)
EP (1) EP1268498B1 (de)
JP (1) JP2003525303A (de)
AT (2) ATE293119T1 (de)
AU (2) AU3718501A (de)
CA (1) CA2401655C (de)
DE (2) DE60133323T2 (de)
DK (1) DK1268498T3 (de)
ES (2) ES2240419T3 (de)
PT (1) PT1268498E (de)
WO (1) WO2001064692A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489345B1 (en) * 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
AU783855B2 (en) 1999-08-24 2005-12-15 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
CA2404329A1 (en) * 2000-03-28 2001-10-04 Medicure International Inc. Treatment of cerebrovascular disease
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
US6822018B2 (en) * 2002-02-15 2004-11-23 Delphi Technologies, Inc. Thermally-conductive electrically-insulating polymer-base material
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
EP1608379A1 (de) * 2003-03-27 2005-12-28 Medicure Inc. Zusammensetzungen zur behandlung von angina
AU2004224562A1 (en) * 2003-03-27 2004-10-07 Medicure Inc. Modulation of cell death
NZ548346A (en) * 2003-12-23 2010-01-29 Medicure Int Inc Combination therapies employing a composition comprising a HMG Co A reductase inhibitor and a vitamin B6 related compound
EP1750862B1 (de) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Irbesartan enthaltende pharmazeutische zusammensetzung
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
AU2005262228A1 (en) * 2004-07-09 2006-01-19 Medicure International Inc. Combination therapies employing nicotinic acid derivatives or fibric acid derivatives
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
JP2008512397A (ja) * 2004-09-10 2008-04-24 メディキュア・インターナショナル・インコーポレーテッド 外傷からの回復のための化合物および方法
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
WO2006050598A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
US20080213364A1 (en) * 2004-11-26 2008-09-04 Medicure International, Inc. Formulations of Pyridoxal-5'-Phosphate and Methods of Preparation
JP2008521756A (ja) * 2004-11-26 2008-06-26 メディキュア インターナショナル インコーポレイテッド ピリドキサール−５’−ホスフェートの新規配合物及び調製方法
JP2008526783A (ja) * 2005-01-05 2008-07-24 メディキュア・インターナショナル・インコーポレーテッド トリグリセリドレベルを調節するための化合物及び方法
CA2503087A1 (en) * 2005-03-30 2006-09-30 Medicure International Inc. Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
WO2007059631A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies
WO2007121588A1 (en) * 2006-04-25 2007-11-01 Medicure International Inc. Treatment of atrial fibrillation
JP2010517939A (ja) * 2007-01-04 2010-05-27 アポセンス リミテッド 細胞の検出のための化合物および方法
WO2014025352A1 (en) * 2012-08-09 2014-02-13 Empire Technology Development Llc Flame retardant nylon
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3206463A (en) 1965-09-14 Pyridoxine aspartate and its process of preparation
FR846376A (fr) 1938-08-23 1939-09-15 Appareillage de navigation aérienne et de bombardement aérien
GB966805A (en) 1961-05-15 1964-08-19 Merck & Co Inc Process for the preparation of 2-methyl-3-hydroxypyridines
NL280553A (de) 1962-07-05
FR5552M (de) 1966-04-28 1967-11-20
FR5801M (de) 1966-06-27 1968-02-19
GB1228142A (de) 1967-03-31 1971-04-15
FR6453M (de) 1967-06-13 1968-11-12
GB1172800A (en) 1967-10-16 1969-12-03 Tanabe Seiyaku Co Novel N-Pyridylmethylidene-Homocysteine Thiolactone Compound and the preparation thereof
DE1767499A1 (de) 1968-05-16 1971-09-09 Merck Patent Gmbh Verfahren zur Herstellung haltbarer Vitaminzubereitungen
ES360566A1 (es) 1968-11-22 1970-10-16 Made Labor Sa Un metodo de obtencion de alfa-cetoglutarato de piridoxina y sus derivados.
GB1236531A (en) 1969-02-12 1971-06-23 Soc D Etudes Prod Chimique Adenin derivative
US3910921A (en) 1970-01-08 1975-10-07 Soc D Etudes Prod Chimique Papaverine monopyridoxal phosphate
GB1297080A (de) 1970-04-17 1972-11-22
FR2101010A1 (en) 1970-08-06 1972-03-31 Lyocentre Sparteine mono-and dipyridoxinates and prepn - as tonics for cardiova disorders
GB1493993A (en) 1975-05-16 1977-12-07 Howard A Dietary supplement and dietary methods employing said supplement for the treatment of obesity
US4053607A (en) 1972-04-04 1977-10-11 Beecham Group Limited Aryloxypyridine for treating hyperglycaemia
US4036844A (en) 1972-04-04 1977-07-19 Beecham Group Limited Aryloxypyridines
GB1360536A (en) 1972-04-25 1974-07-17 Soc D Etudes Prod Chimique Pyridoxyl-l-aspartic acid salt
BE790118A (fr) 1972-10-09 1973-02-01 Made Labor Sa Derives de l'alpha-cetoglutarate de pyridoxal et de pyridoxamine,
US4032534A (en) 1973-03-22 1977-06-28 Ferlus-Chimie S.A. Certain 2-(2-thioethyl)thiazolidine-4-carboxylic acids
FR2255883A1 (en) 1973-12-28 1975-07-25 Centre Etd Ind Pharma Clofibric acid-vitamin B6 compsns. - with synergistic hypocholesterolaemic and normolipaemic activity
FR2275209A1 (fr) 1974-06-21 1976-01-16 Synthelabo Nouveaux esters cetoniques, leurs sels, leur preparation et les medicaments qui les renferment
FR2276048A1 (fr) 1974-06-27 1976-01-23 Synthelabo Nouveaux esters du cyclohexanol, leurs sels, leur preparation et les medicaments qui les renferment
DE2461742C2 (de) 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB1525885A (en) 1976-05-11 1978-09-20 Soc D Etudes Prod Chimique Vincamine salt of pyridoxal phosphate
JPS5417130A (en) 1977-07-08 1979-02-08 Chugai Pharmaceut Co Ltd Remedy for cardio-vasocular diseases
BE863754A (fr) 1978-02-08 1978-05-29 Dechamps Pierre Nouveaux derives de la vincamine utilisables comme regulateurs de la circulation cerebrale
FR2428640A1 (fr) 1978-06-12 1980-01-11 Parcor Derives de pyridoxine, leur procede de preparation et leur application therapeutique
US4167562A (en) 1978-08-28 1979-09-11 Evers H Ray Method and composition for treating arteriosclerosis
IL62602A (en) 1980-05-19 1984-06-29 Labaz Sanofi Nv Pyridoxine derivatives,their preparation and pharmaceutical compositions containing them
IT1141070B (it) 1980-09-22 1986-10-01 Luso Farmaco Inst Impiego dell'alfa-chetoglutarato di piridossina nella profilassi della iperlattacidemia
CA1184499A (en) 1981-06-29 1985-03-26 David C. Madsen Nutritional composition for management of hepatic failure
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4528197A (en) 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
IN160104B (de) 1983-04-05 1987-06-27 Scras
US4735950A (en) 1983-04-05 1988-04-05 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) Furo-(3,4-C)-pyridine derivatives and therapeutic composition containing the same
US4515771A (en) 1983-04-11 1985-05-07 Fine Daniel H Composition and method for the preventative treatment of dental disease and apparatus for dispensing said composition
GB8330517D0 (en) 1983-11-16 1983-12-21 Scras 6-vinyl-furo-(3,4-c)pyridine derivatives
GB8330658D0 (en) 1983-11-17 1983-12-29 Scras 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives
IT1212792B (it) 1983-11-30 1989-11-30 Egidio Aldo Moja Supplemento dietetico e alimento preconfezionato che lo contiene procedimento di preparazione e metodo di somministrazione
US5272165A (en) 1984-03-19 1993-12-21 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US5130324A (en) 1984-03-19 1992-07-14 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
CH664158A5 (fr) 1984-07-18 1988-02-15 Symphar Sa Derives propylidenediphosphonates-1,3 substitues en position 2, leur procede de preparation et compositions pharmaceutiques les contenant.
US4567179A (en) 1984-10-11 1986-01-28 Pfizer, Inc. Antiinflammatory salts of piroxicam
DE3519693A1 (de) 1985-06-01 1987-01-02 Basf Ag Pyridin-derivate, ihre herstellung und verwendung
US4837239A (en) 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US5053396A (en) 1985-08-27 1991-10-01 Blass David H Therapeutic composition
US4735956A (en) 1985-09-13 1988-04-05 Merck & Co., Inc. Certain 1,4-dihydro-2,6-di-lower hydrocarbyl-4-heterocyclic-3,5-pyridine dicarboxylates which are useful as calcium channel blockers
US4605741A (en) 1985-11-13 1986-08-12 Lisapharma Spa Pharmaceutically active salt derivative of 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate
DE3634016A1 (de) 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US5563126A (en) 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
US5631271A (en) 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
NZ222664A (en) 1986-11-29 1990-06-26 Vesta Med Pty Ltd Pharmaceutical compositions containing pyridoxal as a source of vitamin b6
US5254572A (en) 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US4843071A (en) 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
DE3705549A1 (de) 1987-02-18 1988-09-01 Ulrich Speck Verwendung von pyridoxin-derivaten bei der prophylaxe und therapie von hyperlipidaemien und atherosklerose
US5288716A (en) 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
SE8701662L (sv) 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US5213813A (en) 1987-05-29 1993-05-25 The University Of Vermont Pyridoxal-5'-phosphate as an in vitro blood platelet stabilizer
DE58902094D1 (de) 1988-01-28 1992-10-01 Koeltringer Peter Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
NZ228285A (en) 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5254557A (en) 1988-05-09 1993-10-19 Beecham Group P.L.C. Compound and treatment
FR2641189B1 (fr) 1988-06-20 1991-05-10 Timol Mamoojee Compositions pharmaceutiques contenant de l'acide acetyl salicylique et de la vitamine b6
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5001115A (en) 1989-05-17 1991-03-19 University Of Florida Prodrugs of biologically active hydroxyaromatic compounds
GB8918368D0 (en) 1989-08-11 1989-09-20 Amco Chemie Gmbh Compositions for treating obstructive airways disease
DE4016963A1 (de) 1990-05-25 1991-11-28 Steigerwald Arzneimittelwerk Verwendung von magnesium-pyridoxal-5'-phosphat-glutaminat zur verhinderung von erkrankungen, die sich infolge von gefaessschaeden ergeben
US5385937A (en) 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
GB2254556B (en) 1991-04-11 1995-04-12 Fisons Plc Formulations containing linolenic acid
IL101879A (en) 1991-05-15 1998-06-15 Univ Yale Preparation of preparations of pre-pharmacological compounds that can be used for metabolism in the liver for the treatment of liver-related diseases
FR2678622B1 (fr) 1991-07-03 1994-11-18 Adir Nouveaux complexes de vanadium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH07503010A (ja) 1992-01-06 1995-03-30 ヘルス・メインテナンス・プログラムズ，インコーポレイテッド 薬学活性酸化防止剤含有組成物並びに該組成物を使用する血管形成後の再狭窄予防および治療方法
HU217543B (hu) 1992-06-12 2000-02-28 Albert Einstein College Of Medicine Of Yeshiva University Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5330743A (en) 1992-11-12 1994-07-19 Magnetic Research, Inc. Aminosaccharide contrast agents for magnetic resonance images
US5795873A (en) 1992-12-29 1998-08-18 Metabolite Laboratories, Inc. Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6
IT1263957B (it) 1993-02-23 1996-09-05 Impiego terapeutico del pirrolidon carbossilato di piridossina
TW268948B (de) 1993-04-02 1996-01-21 Senju Pharma Co
DE4344751A1 (de) 1993-12-28 1995-06-29 Carl Heinrich Dr Weischer Neue Vitamin B6-Derivate und deren Herstellung und Verwendung als Arzneimittel und als Kosmetika
US5504090A (en) 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
MX9703988A (es) 1994-12-12 1998-02-28 Omeros Med Sys Inc SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
US5569459A (en) 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5733916A (en) 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5833998A (en) 1995-11-06 1998-11-10 The Procter & Gamble Company Topical compositions for regulating the oily/shiny appearance of skin
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5834446A (en) 1996-06-21 1998-11-10 Queen's University At Kingston Nerve process growth modulators
JPH10158244A (ja) * 1996-12-02 1998-06-16 Kissei Pharmaceut Co Ltd ５−アミノアルキル−４−アミノメチル−３−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤
GB9626615D0 (en) * 1996-12-20 1997-02-05 Symphar Sa Novel compounds
US5770215A (en) 1997-01-06 1998-06-23 Moshyedi; Emil Payman Multivitamin/vascular occlusion inhibiting composition
US5804594A (en) 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5944020A (en) 1997-02-25 1999-08-31 Cypros Pharmaceutical Corp. Use of fructose-1 6-diphosphate as an inotrope drug after cardiopulmonary bypass surgery
US5888514A (en) 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation
EP0891719A1 (de) 1997-07-14 1999-01-20 N.V. Nutricia Narungszusammensetzungen mit Gehalt an Methionin
US6051587A (en) * 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US6043259A (en) 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
NZ333023A (en) * 1998-07-09 2000-08-25 Univ Manitoba Treatment of ischemia referfusion injury and treatment of cellular dysfunction including arrhythmia and heart failure subsequent to myocardial infarction using pyridoxal-5'-phosphate, pyridoxine, pyridoxal and pyridoxamine

Also Published As

Publication number Publication date
EP1268498B1 (de) 2005-04-13
EP1268498A1 (de) 2003-01-02
US6605612B2 (en) 2003-08-12
US20030120074A1 (en) 2003-06-26
ES2240419T3 (es) 2005-10-16
DK1268498T3 (da) 2005-08-08
US20030114677A1 (en) 2003-06-19
JP2003525303A (ja) 2003-08-26
ES2305994T3 (es) 2008-11-01
US6667315B2 (en) 2003-12-23
DE60133323D1 (de) 2008-04-30
DE60133323T2 (de) 2009-03-05
WO2001064692A1 (en) 2001-09-07
ATE389662T1 (de) 2008-04-15
US20020010158A1 (en) 2002-01-24
US7105673B2 (en) 2006-09-12
CA2401655A1 (en) 2001-09-07
US20030114678A1 (en) 2003-06-19
DE60110054D1 (en) 2005-05-19
DE60110054T2 (de) 2006-03-09
CA2401655C (en) 2010-06-22
US6867215B2 (en) 2005-03-15
AU3718501A (en) 2001-09-12
PT1268498E (pt) 2005-07-29
US20030181422A1 (en) 2003-09-25
US6780997B2 (en) 2004-08-24
AU2001237185B2 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
ATE389662T1 (de) Cardioprotektive phosphonate
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
NO20071077L (no) Fosfonatanaloger til HIV-inhibitorforbindelser
UA86599C2 (en) Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
WO2005002626A3 (en) Therapeutic phosphonate compounds
CY1106457T1 (el) Φαρμακευτικη συνθεση για τη χρηση σε θepαπεια ορμονικης υποκαταστασεως
ATE490788T1 (de) Antivirale phosphonate analoge
DE60009511D1 (de) Nematizide trifluorbutene
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
ATE433447T1 (de) Pyrimiidinverbindungen
CY1110318T1 (el) Παραγωγα φαινοξυοξικου οξεος
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MY138708A (en) Biaryloxymethylarenecarboxylic acids
TW200630336A (en) Novel compounds
TW200621690A (en) Novel compounds
EA200900373A1 (ru) Реконструированные сурфактанты, обладающие улучшенными свойствами
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
DK0973544T3 (da) Immuntolerant prothrombinkomplekspræparat
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
ES8609312A1 (es) Procedimiento para la preparacion de silibinina exenta de isosilibina
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1268498

Country of ref document: EP

REN Ceased due to non-payment of the annual fee